Back to Search
ISHVINDER GREWAL, MD
MD
Orthopaedic Trauma Physician
NPI: 1306498761IndividualAccepts Medicare
Specialties, Licenses & Credentials
Orthopaedic Trauma PhysicianPrimary
Orthopaedic Surgery — Orthopaedic Trauma
Code: 207XX0801X
BP10069407(TX)ME144998(FL)47325(TX)
CMS Specialties
PrimaryORTHOPEDIC SURGERY
Education
OTHER
Class of 2008
Research & Publications (20)
Novel antibody-based therapeutic agents targeting CD70: a potential approach for treating Waldenström's macroglobulinemia.
PMID 19362984·Clin Lymphoma Myeloma·2009
6-review
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.
PMID 19147785·Blood·2009
7-preclinical
Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.
PMID 19066610·Br J Cancer·2009
7-preclinical
Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
PMID 19047103·Clin Cancer Res·2008
7-preclinical
Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker.
PMID 18809969·Clin Cancer Res·2008
7-preclinical
Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma.
PMID 18477046·Br J Haematol·2008
7-preclinical
CD70 as a therapeutic target in human malignancies.
PMID 18269343·Expert Opin Ther Targets·2008
6-review
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.
PMID 18216294·Blood·2008
7-preclinical
Preclinical safety evaluation of monoclonal antibodies.
PMID 18071940·Handb Exp Pharmacol·2008
6-review
Antibody targeting of B-cell maturation antigen on malignant plasma cells.
PMID 18025285·Mol Cancer Ther·2007
7-preclinical
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.
PMID 17909075·Blood·2007
7-preclinical
Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.
PMID 17038522·Blood·2007
7-preclinical
Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.
PMID 16847437·Br J Pharmacol·2006
7-preclinical
A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys.
PMID 16436662·Am J Pathol·2006
7-preclinical
Developing attributes for a generic quality of life measure for older people: preferences or capabilities?
PMID 16168542·Soc Sci Med·2006
8-other
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
PMID 16357183·Cancer Res·2005
8-other
TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice.
PMID 16174101·Immunol Cell Biol·2005
7-preclinical
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.
PMID 16166310·Cancer Res·2005
7-preclinical
A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response.
PMID 15145935·J Biol Chem·2004
7-preclinical
NTB-A, a new activating receptor in T cells that regulates autoimmune disease.
PMID 14988414·J Biol Chem·2004
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 5201 HARRY HINES BLVD, HOUSE STAFF & GME
DALLAS, TX 75235 - Phone
- (214) 590-8058
Quick Facts
- NPI
- 1306498761
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 2
- Years in Practice
- 18
- Publications
- 20
Are you this provider?
Claim Your Profile